This marker is considered a pan-myeloid in humans and has shown a negative impact on survival in patients with glioblastoma, despite not reaching a statistical significance (29); moreover, Iba1 has been suggested as a prognostic marker and a possible therapeutic target in human hepatocellular carcinomas (30). This evidence concerns the gene AIF1 and hepatocellular carcinoma.